OBJECTIVE: To evaluate clinical, immunological and virological consequences of CD4-guided antiretroviral therapy (ART) planned treatment interruptions (PTIs) compared with continuous therapy in children with chronic HIV infection in the Paediatric European Network for Treatment of AIDS 11 trial. DESIGN: This was a multicentre, 72-week, open, randomized, phase II trial. METHODS:One hundred and nine children with HIV-RNA below 50 copies/ml and CD4% of at least 30% (2-6 years) or at least 25% and CD4 cell count of at least 500 cells/microl (7-15 years) were randomized to continuous therapy (53) or PTI (56). In PTI, ART was restarted if confirmed CD4% was less than 20% or more than 48 weeks had been spent off ART. The primary outcome was Centers for Disease Control and Prevention (CDC) stage C event, death or CD4% less than 15% (and CD4 cell count less than 200 cells/microl for children aged 7-15 years). RESULTS: At baseline, median (interquartile range) age was 9 (6-12) years, CD4% 37% (33-41), CD4 cell count 966 (793-1258) cells/microl, nadir CD4% before combination ART 18% (10-27), time on ART 6 (3-6) years and 26% were CDC stage C. After median (range) 130 (33-180) weeks of follow-up, 4 versus 48% of time was spent off ART in continuous therapy and PTI, respectively. No child died or had a new CDC stage C event; one (2%) continuous therapy versus four (7%) PTI children had a primary outcome based on CD4%/cell count (P = 0.2). Lower nadir CD4% predicted faster CD4% decline after stopping ART. Younger age and higher nadir CD4% predicted being off ART for at least 48 weeks and better CD4% recovery following PTI. CONCLUSION: In this first paediatric trial of PTI, there were no serious clinical outcomes. Younger children had better CD4% recovery after PTIs. Immunology substudies and long-term follow-up in Paediatric European Network for Treatment of AIDS 11 trial are ongoing. Further research into the role of treatment interruption in children is required, particularly, as guidelines now recommend early ART for all infected infants.
RCT Entities:
OBJECTIVE: To evaluate clinical, immunological and virological consequences of CD4-guided antiretroviral therapy (ART) planned treatment interruptions (PTIs) compared with continuous therapy in children with chronic HIV infection in the Paediatric European Network for Treatment of AIDS 11 trial. DESIGN: This was a multicentre, 72-week, open, randomized, phase II trial. METHODS: One hundred and nine children with HIV-RNA below 50 copies/ml and CD4% of at least 30% (2-6 years) or at least 25% and CD4 cell count of at least 500 cells/microl (7-15 years) were randomized to continuous therapy (53) or PTI (56). In PTI, ART was restarted if confirmed CD4% was less than 20% or more than 48 weeks had been spent off ART. The primary outcome was Centers for Disease Control and Prevention (CDC) stage C event, death or CD4% less than 15% (and CD4 cell count less than 200 cells/microl for children aged 7-15 years). RESULTS: At baseline, median (interquartile range) age was 9 (6-12) years, CD4% 37% (33-41), CD4 cell count 966 (793-1258) cells/microl, nadir CD4% before combination ART 18% (10-27), time on ART 6 (3-6) years and 26% were CDC stage C. After median (range) 130 (33-180) weeks of follow-up, 4 versus 48% of time was spent off ART in continuous therapy and PTI, respectively. No child died or had a new CDC stage C event; one (2%) continuous therapy versus four (7%) PTI children had a primary outcome based on CD4%/cell count (P = 0.2). Lower nadir CD4% predicted faster CD4% decline after stopping ART. Younger age and higher nadir CD4% predicted being off ART for at least 48 weeks and better CD4% recovery following PTI. CONCLUSION: In this first paediatric trial of PTI, there were no serious clinical outcomes. Younger children had better CD4% recovery after PTIs. Immunology substudies and long-term follow-up in Paediatric European Network for Treatment of AIDS 11 trial are ongoing. Further research into the role of treatment interruption in children is required, particularly, as guidelines now recommend early ART for all infected infants.
Authors: A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch Journal: HIV Med Date: 2015-02-03 Impact factor: 3.180
Authors: Gabriela Patten; Michael Schomaker; Mary-Ann Davies; Helena Rabie; Gert van Zyl; Karl Technau; Brian Eley; Andrew Boulle; Russell B Van Dyke; Kunjal Patel; Nosisa Sipambo; Robin Wood; Frank Tanser; Janet Giddy; Mark Cotton; James Nuttall; Gadija Essack; Brad Karalius; George Seage; Shobna Sawry; Matthias Egger; Lee Fairlie Journal: Pediatr Infect Dis J Date: 2019-04 Impact factor: 2.129
Authors: George K Siberry; Kunjal Patel; Russell B Van Dyke; Rohan Hazra; Sandra K Burchett; Stephen A Spector; Mary E Paul; Jennifer S Read; Andrew Wiznia; George R Seage Journal: J Acquir Immune Defic Syndr Date: 2011-07-01 Impact factor: 3.731
Authors: Adam W Bartlett; Pagakrong Lumbiganon; Nia Kurniati; Tavitiya Sudjaritruk; Thahira J Mohamed; Rawiwan Hansudewechakul; Penh S Ly; Khanh H Truong; Thanyawee Puthanakit; Lam V Nguyen; Kulkanya Chokephaibulkit; Viet C Do; Nagalingeswaran Kumarasamy; Nik Khairulddin Nik Yusoff; Moy S Fong; Dewi K Watu; Revathy Nallusamy; Annette H Sohn; Matthew G Law Journal: J Adolesc Health Date: 2019-08-05 Impact factor: 5.012
Authors: Mark F Cotton; Avy Violari; Kennedy Otwombe; Ravindre Panchia; Els Dobbels; Helena Rabie; Deirdre Josipovic; Afaaf Liberty; Erica Lazarus; Steve Innes; Anita Janse van Rensburg; Wilma Pelser; Handre Truter; Shabir A Madhi; Edward Handelsman; Patrick Jean-Philippe; James A McIntyre; Diana M Gibb; Abdel G Babiker Journal: Lancet Date: 2013-11-09 Impact factor: 79.321
Authors: Emmanuel C Nwosu; Martha J Holmes; Mark F Cotton; Els Dobbels; Francesca Little; Barbara Laughton; Andre van der Kouwe; Ernesta M Meintjes; Frances Robertson Journal: IBRO Neurosci Rep Date: 2021-02-10
Authors: Linda Harrison; Jintanat Ananworanich; Djamel Hamadache; Alexandra Compagnucci; Martina Penazzato; Torsak Bunupuradah; Antonio Mazza; Jose Tomas Ramos; Jacquie Flynn; Osvalda Rampon; Maria Jose Mellado Pena; Daniel Floret; Magdalena Marczynska; Ana Puga; Silvia Forcat; Yoann Riault; Marc Lallemant; Hannah Castro; Diana M Gibb; Carlo Giaquinto Journal: AIDS Behav Date: 2013-01